{
  "nctrialId": "HC-1449",
  "title": "A Randomized Double-Blind, Active-Controlled  Study of AST-611 (anti-IL-5 antibody) in Patients With Alzheimer's Disease",
  "officialTitle": "A Randomized Double-Blind, Active-Controlled  Study of AST-611 (anti-IL-5 antibody) in Patients With Alzheimer's Disease",
  "sponsor": "BC Cancer Agency",
  "indication": "Alzheimer's Disease",
  "phase": "Phase 3",
  "fileName": "HC-1449.json",
  "fileSize": 301306,
  "date": "2023-11-01",
  "completionDate": "2029-03-26",
  "drugName": "AST-611 (anti-IL-5 antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Active, not recruiting",
  "description": "This is a randomized double-blind, active-controlled  study designed to evaluate the efficacy and safety of AST-611 (anti-IL-5 antibody) in patients with Alzheimer's Disease. The study will enroll approximately 77 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-63 years\n- Confirmed diagnosis of Alzheimer's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}